Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9512480.6Aexternal-prioritypatent/GB9512480D0/en
Priority claimed from GBGB9513415.1Aexternal-prioritypatent/GB9513415D0/en
Priority claimed from PCT/EP1995/004110external-prioritypatent/WO1996012742A1/en
Application filed by Glaxo Group LtdfiledCriticalGlaxo Group Ltd
Publication of MX9702772ApublicationCriticalpatent/MX9702772A/es
Publication of MXPA97002772ApublicationCriticalpatent/MXPA97002772A/es
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
Agentes enlazantes a CD11b, CD11c, CD23, una proteína KDa 70 a 85 expresada en células endoteliales o una proteína KDa 115 expresada en células endoteliales, puede ser utiles en el tratamiento de padecimientos inflamatorios autoinmunes o alérgicos.
MXPA/A/1997/002772A1994-10-251997-04-16Agentes enlazantes para el tratamiento de padecimientos inflamatorios, autoinmunes o alergicos
MXPA97002772A
(es)